<DOC>
	<DOCNO>NCT02229123</DOCNO>
	<brief_summary>LEVNEONAT multicentre French clinical trial aim develop new treatment strategy treatment neonatal seizure use Levetiracetam . The purpose study determine correct dosing , safety efficacy intravenous levetiracetam first line treatment term new born baby seizures . This new anticonvulsivant drug promise treatment seizure newborn .</brief_summary>
	<brief_title>Levetiracetam Treatment Neonatal Seizures : Safety Efficacy Phase II Study</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>male female term baby gestational 3743 week postnatal age &lt; or= 72 hour one follow : APGAR score &lt; 5 5 min Umbilical cord arterial blood sample ( within one hour birth ) : pH &lt; 7.0 base deficit &gt; 16 mmol/L Postnatal resuscitation still require 10 minute birth Clinically evolve encephalopathy EEG : equal 3 min cumulative seizure , 2 seizure &gt; 30 sec duration 2 hour period within 72 hour life Written inform consent parent guardian EEG monitoring commence within first 72 hour birth Suspected confirm brain malformation , inborn error metabolism , genetic syndrome major congenital malformation Congenital ( utero ) infection ( TORCH ) Babies receive phenobarbitone anticonvulsive medication bolus midazolam intubation within last 24 hour Anuria/renal failure define serum creatinine &gt; 150 micromol/L</criteria>
	<gender>All</gender>
	<minimum_age>37 Weeks</minimum_age>
	<maximum_age>43 Weeks</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>seizure</keyword>
	<keyword>neonate</keyword>
	<keyword>anticonvulsant treatment</keyword>
	<keyword>levetiracetam</keyword>
	<keyword>hypoxic-ischemic encephalopathy</keyword>
	<keyword>electroencephalography</keyword>
</DOC>